FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and medicine, in particular to a method for diagnosing T-cell lymphoma or leukaemia in a subject, comprising a step of determining the percentage of T-cells that are TRBC1- or TRBC2-positive of the total number of T-cells in a sample, as well as to a method of selecting a suitable therapy for treating a subject having T-cell lymphoma or leukaemia, and a method of selecting a subject having T-cell lymphoma or leukaemia to receive a CAR-T cell therapy. Methods are carried out using an agent which contains an antigen-binding domain which selectively binds to a constant region of 1 TCR beta (TRBC1) or TRBC2.
EFFECT: invention provides a new method for targeted therapy of T-cell malignant neoplasms.
11 cl, 27 dwg, 5 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
| TNF RECEPTOR-BINDING AGONISTS | 2016 |
|
RU2821343C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| ANTIBODY AGAINST PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR AND APPLICATION THEREOF | 2019 |
|
RU2778023C1 |
